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Toxicity and TNF Production in Glucocorticoid-
Sensitive and Glucocorticoid-Resistant Models of
Endotoxic Shock
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Mario Zandalasini, Alberto Mantovani, and Pietro Ghezzi
From the Istituto di Ricerche Farmacologiche "Mario Negri, via Eritrea 62, 20157 Milan, Italy
Summary
The present study was designed to define the potential ofchlorpromazine (CPZ) as a protective
agent against lipopolysaccharide (LPS) toxicity in comparison with glucocorticoids, and to obtain
initial correlations with its effects on the levels of tumor necrosis factor (TNF), a pivotal mediator
of endotoxic shock . It was found that CPZ protects mice, normal or adrenalectomized, and guinea
pigs against lethality of LPS, and inhibited TNF serum levels, like dexamethasone (DEX), a
well-known inhibitor ofTNF synthesis. CPZ protected against LPS lethality when administered
30 minutes (min) before, simultaneously, or up to 10 min after LPS and was ineffective when
given 30 min after LPS, paralleling the inhibitory effect on TNF production . In another experimental
model, where mice were sensitized to LPS toxicity by actinomycin D, CPZ significantly inhibited
LPS lethality and hepatotoxicity, whereas under these conditions DEX was inactive . These
experiments indicate that CPZ has a protective action in both glucocorticoid-sensitive and -resistant
models of endotoxic shock .
Tumor necrosis factor (TNF) is a key mediator in the toxiceffect ofendotw in (LPS) and in the pathogenesis of septic
shock . In fact, serum levels of TNF are high after LPS ad-
ministered to animals and human volunteers, or in septic pa-
tients (1, 2), while administration of antiTNF antibodies pro-
tects against the lethal effect of LPS and live bacteria in a
variety of animal models (3, 4) .
AntiTNF antibodies are also protective in a variety of an-
imal models of human diseases, including cerebral malaria
(5), bacterial meningitis (6), bleomycin lung toxicity (7), liver
ischemia/reperfusion damage (8), and graft-versus-host reac-
tion (9), indicating an involvement ofTNF in the pathogen-
esis of these diseases . Therefore, TNF might be an impor-
tant target for pharmacological action, and inhibitors of its
synthesis might be useful in the therapy of these diseases .
The well-known inhibitory effect ofglucocorticoids on TNF
synthesis is thought to be connected with protective action
of glucocorticoids in endotoxic shock (10-12).
Previous data from this laboratory have shown that chlor-
promazine (CPZ)t protects mice against the lethal effect of
LPS and IL1, but not ofTNF (13) . The objective ofthe present
study was to define the potential of CPZ to block LPS tox-
icity in comparison with glucocorticoids and to obtain ini-
1 Abbreviations used in this paper. Act D, actinomycin D : CPZ, chlor-
promazine; DEX, dexamethasone; GPT, glutamate pyruvate transaminase .
1305
tial correlations with its effect on the levels of TNF. For this
purpose, we have studied the effect of CPZ on LPS toxicity
and induction of TNF in various experimental models, in-
cluding : (a) high-dose LPS (30 mg/kg) in mice, (b) adminis-
tration of LPS (5 mg/kg) in guinea pigs, which are more
sensitive to LPS than mice in terms of lethality and TNF
induction (14), (c) adrenalectomized mice, known to be more
sensitive to LPS toxicity and TNF induction (11, 15), and
(d) mice pretreated with actinomycin D (Act D), which present
increased sensitivity to LPS (comparable to that of adrenalec-
tomized mice) through a mechanism that is still not clear
(10, 16) . In these experimental models, the activity of CPZ
was compared with that of dexamethasone (DEX), which
inhibits TNF production and protects against LPS toxicity
in some animal models (10-12) . Since some animal models
of endotoxic shock appear to be resistant to glucocorticoids,
and clinical studies have indicated that glucocorticoid therapy
might not be effective in septic patients (17, 18), the com-
parison of CPZ and DEX might indicate any possible advan-
tages in the use of CPZ in those situations where glucocorti-
coids are ineffective.
Materials and Methods
Animals, Drugs, and Cytokines.
	
Male adult (25-28 g) CD1 mice,
obtained from Charles River Italia (Calco, Como, Italy) were used,
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unless otherwise indicated . All treatments were given by i.p. injec-
tion in 0.2 ml ofsterile pyrogen-free saline, between 9.00 and 1.00
a.m. LPS (Westphal preparation from Escherichia coli 055:135) was
from Sigma Chemical Co. (St . Louis, MO), CPZ (Largactil, Far-
mitalia Carlo Erba, Milano, Italy) and DEX phosphate (Far-
macologico Milanese, Milan, Italy) were given intraperitoneally 30
min before LPS at doses of4 and 30 mg/kg, respectively (13) . Sur-
vival was assessed every day on at least 10 animals per group and
statistical analysis was done using Fisher's exact test . TNF levels
were measured in sera obtained 1 h after LPS (unless otherwise
indicated) by cytotoxicity on L929 cells (19), and expressed as ng/ml
by comparison with a standard of human recombinant TNF (sp
act, 107 U/mg). Liver damage was evaluated by measuring serum
glutamate pyruvate transaminase (GPT) using a commercially avail-
able kit (Boehringer, Mannheim, Mannheim, Germany) .
Adrenalectomized Mice.
	
Mice were bilaterally adrenalectomized
under ether anesthesia and were kept for 10 d to recover before
the experiment . They were given 0.9% NaCI in drinking water.
Mice were treated with 75 Fg/kg ofLPS, as previously described
(11) and survival was assessed daily.
Act D-Sensitized Mice. Mice were treated with Act D (0 .6
mg/kg), 10 min before LPS (30 ug/kg), as previously described
(16), and hepatotoxicity was assessed on the basis of serum GPT
measured 7 h after treatment .
High-Dose LPS Toxicity. Male, adult (22-24 g) Balb/C mice
were used (Charles River Italia) . They were given LPS at the dose
of 30 mg/kg and survival was assessed daily.
Guinea Pigs. Male guinea pigs weighing 275-300 g (Charles
RiverItalia) were used . LPS was administered at thedose of5 mg/kg
and survival was assessed daily.
Results
In a first set ofexperiments, we studied the effect ofpretreat-
ment with CPZ (4 mg/kg) or DEX (30 mg/kg) on TNF
production in CD1 mice given a nontoxic dose of LPS (75
Ag/kg) . The time course of TNF production is shown in
Fig . 1 . Peak TNF levels were observed after 1 h, and both
CPZ and DEX almost completely blocked the release ofTNF.
The effect of CPZ and DEX was then studied on the
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Figure 1 . Effect ofCPZ and DEX on serum TNF in LPS-treated mice .
Mice were treated with 75 ug/kg of LPS, with or without CPZ or DEX
pretreatment, as described in the text . Data are mean ± SD (five
mice/group) .
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Figure 2 . Effect of CPZ and DEX on LPS toxicity (A) and induction
of serum TNF (B) in Balb/C mice. Mice were treated with 30 mg/kg
of LPS, with orwithout CPZ or DEX pretreatment, as described before .
Survival was assessed daily on groups of 15 mice . Serum TNF levels were
measured 1 h after LPS treatment . Data are mean ± SD (five mice/group) .
" p < 0.01 vs LPS alone by Student's t-test .
lethality of high-dose LPS. Balb/C mice were used since in
preliminary experiments CD1 mice were found to be extremely
resistant to the toxic effects of high doses of LPS. As shown
in Fig . 2 A, 30 mg/kg of LPS caused the death of 100%
of the mice within 4 d . Both CPZ and DEX completely pro-
tected against LPS toxicity. The same figure (B), shows serum
TNF levels 1 h after LPS in the same experimental condi-
tions . Both drug inhibited TNF production, thus paralleling
the data on mortality.
Using this experimental model we have studied the effect
of different schedules ofCPZ treatment on LPS toxicity and
serum TNF levels. As shown in Fig. 3, CPZ had maximal
protective effect on LPS toxicity and TNF production when
given as a pretreatment (30 min before LPS) . The effective-
ness of CPZ was still significant when administered simul-
taneously with or 10 min after LPS both on lethality and
TNF production . The efficacy of CPZ disappeared when it
was administered as late as 30 min after LPS .
A dose response of the effect of CPZ on LPS toxicity and
TNF production is presented in Fig. 4 . It can be seen that
the optimal dose to give a protection against LPS toxicity
is 4 mg/kg. A protective effect was still evident at 1 mg/kg
and disappeared below 0.25 mg/kg or when CPZ dose was
increased at 8 mg/kg. When the inhibitory effect ofdifferent
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Figure 3 . Time-dependency of the protective effect of CPZ on LPS
lethality and TNF induction in Balb/C mice. Mice were treated with 30
mg/kg of LPS, with or without CPZ . CPZ was given 30 min before,
simultaneously with, 10, 20, or 30 min after LPS. Survival was assessed
daily on groups of 15 mice. Serum TNF levels were measured 1 h after
LPS treatment . Data are mean ± SD (five mice/group) . ' p < 0.01 vs
LPS alone by Student's nest .
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Figure 4 . Effect of different doses of CPZ on LPS lethality and TNF
production in Balb/C mice. Mice were treated with 30 mg/kg of LPS,
with or without CPZ . CPZ was given 30 min before LPS at the indicated
dose. Survival was evaluated 5 d after LPS treatment . Serum TNF levels
were measured 1 h after LPS treatment . Data are mean ± SD (five
mice/group) . " p < 0.01 vs LPS alone by Student's t-test.
doses ofCPZ on TNF production was investigated, an inhi-
bition was also observed with the lowest doses tested but
the minimal effective dose to attain an almost complete inhi-
bition was 1 mg/kg . Interestingly enough, at the highest
dose (8 mg/kg) CPZ completely inhibited TNF production
but did not improve survival of mice.
The effects ofpretreatment with CPZ and DEX in guinea
pigs given 5 mg/kg LPS are reported in Fig. 5. A high mor-
tality (82%) was observed in guinea pigs within the first day
after LPS. Guinea pigs also had high TNF levels, compared
to mice, in agreement with previous reports on their high
susceptibility to LPS (14) . In this case too, CPZ markedly
Figure 5. Effect of CPZ and DEX on LPS toxicity (A) and induction
ofserum TNF (B) in guinea pigs. Guinea pigs were treated with 5 mg/kg
of LPS with or without CPZ or DEX pretreatment as described before.
Survival was assessed dailyon groups of 16 guinea pigs. Serum TNF levels
were measured 1 h after LPS treatment . Data are mean ± SD (five guinea
pigs/group) . ' p < 0.01 vs LPS alone by Student's t-test .
Ja
0
E
u-
Z
1-
LPS CPZ/LPS DEX/LPS
LPS CPZ/LPS DEX/LPS
Figure 6.
	
Effect ofCPZ and DEX on LPS toxicity (A) and induction
of serum TNF (B) in adrenalectomized mice. Mice were treated with 75
fag/kg of LPS with or without CPZ or DEX pretreatment as described
before. Lethality was evaluated on groups of 15 mice 2 d after LPS treat-
ment, and no further deaths were observed up to 8 d. Serum TNF levels
were measured 1 h after LPS treatment . Data are mean ± SD (five
mice/group) . " p < 0.01 vs LPS alone by Student's t test (TNF levels) or
p < 0.05 by Fisher's exact test (lethality) .
protected against LPS toxicity and inhibited TNF produc-
tion, although it was less potent than DEX.
CPZ andDEX were then tested in adrenalectomized mice,
and the results are reported in Fig. 6. In this experimental
model, 100% toxicity was observed after low doses of LPS
(75 NAg/kg). CPZ andDEXonce again had a significant pro-
tective effect, confirming our previous findings (13) . Both
drugs also inhibited TNF production in adrenalectomized
mice.
Finally, we used a murine model where sensitization to
LPS is achieved by pretreatment with Act D. LPS toxicity
in this experimental model is associated with a marked
hepatotoxicity, and serum GPT levels were also measured.
As shown in Fig. 7 A, 100% lethality was observed when
a dose of LPS as low as 30 /Ag/kg was given after Act D.
Pretreatment with CPZ had a marked protective effect against
Act D/LPS toxicity, while DEX was only marginally effec-
tive. However, as shown in Fig. 7 B, both drugs inhibited
TNF release in this experimental model. Indeed, the inhibi-
tory effect ofDEXwas even stronger than that of CPZ. When
serum GPT were measured in moribund animals, 7 h after
Act D/LPS (Fig. 7 C), it was evident that only CPZ, not
DEX, protected against Act D/LPS hepatotoxicity.
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Figure 7. Effect of CPZ and DEX pretreatment on LPS toxicity and
induction of serum TNF in mice treated with 30 Fig/kg of LPS and
0.6 mg/kg of Act D (see Materials and Methods) . (A) lethality was
evaluated on groups of 15 mice 2 d after LPS treatment, and no further
deaths were observed up to 8 d. ' p< 0.05 vs LPS alone by Fisher's exact
test . (B) serum TNF levels were measured 1 h after LPS treatment (data
are mean ± SD of five mice/group) . ' p < 0.01 vs LPS alone by Student's
t-test . (C) serum GPT levels were measured 7 h after LPS treatment (data
are mean ± SD of seven mice/group) . "' p < 0.01 vs LPS alone by Stu-
dent's t-test .
The present study indicates that CPZ has a protective effect
against the toxicity ofLPSin various animal models. In three
experimental models, normal and adrenalectomized mice and
guinea pigs, CPZ was less effective than DEX. In these ex-
perimental models, the protective effect of CPZ in terms of
survival was associated with an inhibition of serumTNFlevels,
similarly to what was observed with DEX. Furthermore, CPZ
had a protective effect against LPS toxicity in Act D-sensitized
mice, although in this case the interpretation of the results
is more difficult .
Like galactosamine, Act D potentiates the toxicity ofLPS
(10, 16, 20) . It was suggested this was due to inhibition of
hepatic protein synthesis, and in fact fulminant hepatitis was
observed in galactosamine/LPS-treated mice. The mechanism
of this hepatotoxic effect has not yet been clarified, but seems
to involve damage similar to that following ischemia/reper-
fusion (20) . This experimental model differs from the other
models studied in many respects . In particular, there was no
protection by DEX and toxicity (lethality and liver damage)
did not correlate with TNF production, which was blocked
by DEX. Finally, in all the other experimental models there
was no hepatotoxicity, since no transaminase levels were de-
tected in moribund animals (data not shown) . Therefore, in
Act D-sensitized mice, toxicity seems not to be mediated only
by TNF and, more importantly, is resistant to glucocorti-
coids. The effectiveness of CPZ in an experimental model
of DEX-resistant LPS toxicity is particularly interesting if
we consider that recent clinical trials indicated that high-dose
glucocorticoids are ineffective in the treatment of severe sepsis
and septic shock (17, 18) .
The mechanism by which CPZ exerts its protective effect
is still unclear, but the data reported here indicate that inhi-
bition of TNF production might have a key role. In fact,
when different schedules of CPZ administration were used,
it was found that the ability of CPZ to protect against LPS
lethality paralleled the inhibition of TNF production, fur-
ther supporting the view of TNF being the key mediator
of LPS toxicity. Similar results were obtained with dose-
response experiments (Fig. 5), where a marked protective effect
on LPS toxicity was obtained only with CPZ doses effective
in completely inhibiting TNF production . The optimal dose
of CPZ was found to be 4 mg/kg, while higher doses, while
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still inhibiting TNF production were not effective on LPS
toxicity in the same mice . However it should be noted that
CPZ at this dose had a strong hypotensive effect that might
well oppose the protective action due to inhibition of TNF
production .
As far as the mechanism of the inhibitory effect on TNF
production is concerned, previous reports indicated that CPZ
inhibits the induction of mRNA for IL2, IFN-7 and TNF
in thymocytes (21) and inhibits the secretion of IL1 by mono-
cytes (22) . It is possible that inhibition of TNF production
reported in this paper is mediated by the calcium antagonizing
activity of CPZ, as it was suggested for its inhibition of IL-1
secretion .
Although extrapolation ofthis data to man will obviously
require further studies, it should be noted that the plasma
levels of CPZ in rats and mice treated with doses of CPZ
that inhibit TNF production in this study are well in the
range (50-600 ng/ml) observed in patients treated with phar-
macologically effective doses of CPZ (23-25) .
On the other hand, the protective action of CPZ in Act
D-sensitized mice, where inhibition ofTNF production was
not sufficient to protect against LPS toxicity (as indicated
by the ineffectiveness of DEX) indicates that CPZ might act
by some mechanisms different from those of DEX and pos-
sibly not only by inhibiting TNF production . In this respect
it is important to consider that CPZ has a wide range ofphar-
macological activities, ranging from antipsychotic and anti-
histaminic action (23) to inhibition ofphospholipase A2 (26),
all of which could be important for the reported protective
effect . It is clear that its mode of action in protecting against
LPS toxicity and inhibiting TNF production needs to be elu-
cidated and could provide useful indications for the therapy
of septic shock and other cytokine-mediated pathologies .
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